Two Phase 3 trials demonstrated that COMP360 provides rapid and durable relief for treatment-resistant depression, with effects lasting at least 26 weeks and a favorable safety profile. Regulatory review is progressing, and commercial launch is targeted for 2027.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.